Although a relationship between paclitaxel and the intracellular Bcl-2 family has been reported [69], in which the Bcl-2 family acts in ovarian cancers that have been resensitized to paclitaxel, glutamine metabolism inhibition has not yet been elucidated. This evidence concerns the gene BCL2 and ovarian carcinoma.